Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

147.39 -1.62 (-1.09%)
Delayed Quote Updated: 1:54 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Insulet (NASDAQ:PODD): A Growth-at-a-Reasonable-Price Case With Strong Expansion ↗
Via Chartmill
News headline image
2 Profitable Stocks to Keep an Eye On and 1 We Question
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
2 of Wall Street’s Favorite Stocks to Target This Week and 1 We Ignore
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
2 Safe-and-Steady Stocks to Consider Right Now and 1 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi... 
Via StockStory
Insulet (NASDAQ:PODD) Offers Affordable Growth With Strong Fundamentals ↗
Via Chartmill
Insulet (NASDAQ:PODD): Growth at a Reasonable Valuation ↗
Via Chartmill
Insulet (NASDAQ:PODD) Shares Tumble on Reduced Full-Year Outlook Despite Q2 Earnings Beat ↗
Via Chartmill
News headline image
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum ↗
Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated... 
Via MarketBeat
News headline image
2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) ... 
Via StockStory
Topics Artificial Intelligence
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors? ↗
McEvoy invested $162,217 at a weighted average price of $147.47, bringing total beneficial ownership to 23,735 shares valued at $3.52 million. 
Via The Motley Fool
Topics Regulatory Compliance
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
3 Mid-Cap Stocks with Competitive Advantages
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulator... 
Via StockStory
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Insulet (PODD) Q2 2026 Earnings Call Transcript ↗
Type 2 retention challenges force management to trim full-year outlook despite revenue beat. 
Via The Motley Fool
Topics Earnings
News headline image
5 Must-Read Analyst Questions From Insulet’s Q2 Earnings Call
Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the comp... 
Via StockStory
Topics Earnings
News headline image
These Analysts Slash Their Forecasts On Insulet After Q2 Results ↗
Insulet Corp. (NASDAQ:PODD) reported strong Q2 earnings but lowered revenue outlook for 2021. Analysts downgraded stock and lowered price targets. 
Via Benzinga
News headline image
PODD Q2 Deep Dive: Retention Challenges in Type 2 Diabetes Temper Growth Outlook
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 23.5% year on ... 
Via StockStory
News headline image
Why Insulet (PODD) Shares Are Sliding Today
What Happened? Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) fell 20.5% in the afternoon session after the company reported strong sec... 
Via StockStory
Topics Economy
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Insulet Q2 Earnings Call Highlights ↗
Insulet (NASDAQ:PODD) reported second-quarter revenue growth of 23% on a constant-currency basis, supported by demand for its Omnipod insulin-delivery system in the U.S. and international markets,... 
Via MarketBeat
Topics Earnings
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Insulet’s (NASDAQ:PODD) Q2 CY2026 Sales Top Estimates But Stock Drops
Insulin delivery company Insulet Corporation (NASDAQ:PODD) announced better-than-expected revenue in Q2 CY2026, with sales up 23.5% year on year to $801.7 mi... 
Via StockStory
News headline image
Insulet (PODD) Reports Earnings Tomorrow: What To Expect
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what you need to know. Insulet beat anal... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.